IGR-1 Cells
USUSD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | The IGR-1 cell line is derived from a human malignant melanoma, making it a valuable model for studying the pathophysiology of melanoma and testing anti-cancer therapies. These cells are epithelial in nature and exhibit characteristics typical of aggressive melanoma, including rapid proliferation and the ability to form colonies in soft agar, a hallmark of oncogenic transformation. The IGR-1 cell line is particularly useful in research focused on understanding the molecular mechanisms driving melanoma progression, as well as in the development and testing of targeted therapies and immunotherapies. IGR-1 cells harbor mutations common in melanoma, including alterations in the MAPK/ERK pathway, which is often dysregulated in this cancer type. These mutations contribute to the cell line's ability to proliferate uncontrollably and resist apoptosis. Researchers utilize IGR-1 cells to investigate the effects of various inhibitors on this signaling pathway, providing insights into potential therapeutic strategies. Additionally, the cell line's expression of melanoma-associated antigens makes it suitable for studying immune responses against melanoma, including the development of novel immunotherapeutic approaches. |
|---|---|
| 生物體 | Human |
| 組織 | Skin |
| 疾病 | Malignant melanoma |
| 轉移部位 | Groin lymph node |
| 同義詞 | IGR 1, IGR1, Institut Gustave Roussy-1 |
特徵
| 年齡 | 42 years |
|---|---|
| 性別 | Male |
| 形態學 | Polygonal |
| 生長特性 | Adherent |
監管數據
| 引用 | IGR-1 (Cytion catalog number 300219) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_1303 |
生物分子資料
| 致瘤性 | Yes, in nude mice. |
|---|---|
| 產品 | Melanin |
| 突變譜 | IGR-1 cells carry a heterozygous BRAFV600K mutation, but they are wild type with respect to BRAFV600E. |
處理方式
| 培養基 | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS |
| 解離試劑 | Accutase |
| 傳代培養 | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| 播種密度 | 3 x 104/cm2 after thawing, 1 to 2 x 104/cm2 for routine splitting |
| 流體更新 | 2 to 3 times per week |
| 解凍後的恢復 | 1 to 2 days |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 300219-814SF | 分析證明書 | 23. May. 2025 | 300219 |
| 300219-020224 | 分析證明書 | 23. May. 2025 | 300219 |
| 300219-271025 | 分析證明書 | 05. Dec. 2025 | 300219 |